MSK 2020 Virtual Update on the Treatment of Pituitary Tumors: Emerging Therapies

MSK 2020 Virtual Update on the Treatment of Pituitary Tumors: Emerging Therapies is organized by Memorial Sloan Kettering Cancer Center (MSKCC). This online CME course will be held as a fully web-based course on December 05, 2020.

AMA Credit Designation Statement:
Memorial Sloan Kettering Cancer Center assigns this online CME activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians will be able to earn only the credit commensurate based on the extent of their participation in the activity. 

ABIM MOC Recognition Statement:
Successful completion of this CME activity, which involves participation in the evaluation component, allowing the participant to earn up to 5.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Course Overview:
After the conclusion of this didactic and case-based educational activity, respondents will be up to date on the newest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions. Participants will be able to:
• Outline available and emerging medical therapies for Cushing’s and acromegaly
• Consider distinct therapies for aggressive and malignant tumors
• Know decision making involved in surgical intervention for pituitary tumors
• Give an overview of potential surgical complications
• Obtain and Describe the role of radiation therapy for pituitary tumors
• Analyze neuro-ophthalmological findings in pituitary disease risks
• Discuss the treatment of immunotherapy-related pituitary dysfunction
• Assess advances in neuroimaging and tumor markers that may predict tumor behavior and clinical outcomes

Overall this course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies. Our goal is to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for the dissemination of knowledge across the variety of practitioners caring for pituitary patients, and for the patients themselves.

Provider/Clinical Track
Request for Case Submissions - There will be a tumor board during the provider/clinical breakout session where attendees and faculty will review cases. Attendees will have an opportunity to submit a case for discussion during the course at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and they will try to get through as many cases as possible.

Patient Track:
We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions. Pituitary patients will be able to review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients.

MSK is pleased to invite patients and caregivers to attend this course on a complimentary basis. If you are a patient or caregiver interested in attending, please email cme@mskcc.org to register (registration is required in order to attend). 

Objectives:
• Evaluate the efficacy and side effect profiles of treatment options, including emerging therapies, for Cushing’s and acromegaly
• Consider surgical outcomes and risk management for pituitary and skull base tumors
• Explain current advances in pituitary neuropathology and neuroimaging
• Critically appraise the role of radiation therapy in the management of pituitary tumors
• Discuss treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
• Present a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients

Endorsed by:
Pituitary Network Association (PNA)
Cushing’s Support & Research Foundation (CSRF)
Acromegaly Community